A researcher from the Neurobiology of Hearing group participates in a clinical trial of a new treatment for hereditary angioedema
Dr. Maria Luisa Baeza from the Neurobiology of Hearing group has participated in a Phase III clinical study ((EudraCT 2013-000916-10, ClinicalTrials.gov NCT01912456) to evaluate the efficacy and safety of the C-1 inhibitor CSL830 in the treatment of hereditary angioedema The results of this trial indicate that the subcutaneous administration of CSL830 decreases the number of attacks of hereditary angioedema per month, with the majority of patients presenting a low profile of side effects. This work has been published in the prestigious New England Journal of Medicine Longhurst et al. Prevention of Hereditary Angioedema Attacks with Subcutaneous C1-Inhibitor. NEJM 2017 Mar 23;376(12):1131-1140
A new molecule evaluated by the Neurobiology of Hearing group, authorized by the FDA to conduct Phase 1 clinical trial
Biopharmaceutical Company Spiral Therapeutics, Inc. has obtained the authorization from the US Food and Drug Administration (FDA) to start in early 2018 of a phase 1 clinical trial with LPT99, a new molecule for the treatment of chemotherapy-induced hearing loss in pediatric patients. LPT99 is a small molecule with strong anti-apoptotic activity. LPT99 is administered transtympanically in a hydrogel formulation to effectively reach the hair cells in the inner ear. This molecule has confirmed to be safe and effective in the animal model tests carried out by the Neurobiology of Hearing group, within the framework of an agreement with that company that began in 2015 and continues today.
Scientists from the IIBM “Alberto Sols” CSIC-UAM attempt to develop a new kind of immunotherapy to target the cancer stem cells in pancreatic cancer
The group of Dr. Bruno Sainz Anding, Ramón y Cajal Investigator from the Department of Biochemistry at the Universidad Autónoma de Madrid, the Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM) and the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), are working to develop new monoclonal antibodies that will help the immune system identify and attack pancreatic cancer, which currently lacks effective immunotherapy-based treatments. The project recently received a research grant of 60,000 euros from the Pancreatic Cancer Association (ACANPAN) and the Spanish Association of Pancreatology (AESPANC). https://www.asociacioncancerdepancreas.org/beca-investigaci%C3%B3n/ "We seek to take an important step forward in the development of new therapies against these tumors," explains Dr. Sainz, who recalls that...
The Spanish Confederation of Families of Deaf People (FIAPAS) held the ceremony for the presentation of its Prize for Research in Hearing Deficiencies on Wednesday, July 5, chaired by Dolors Montserrat, Minister of Health, Social Services and Equality. One of the two award-winning researches in the Health Category is a study conducted by researchers at the Neurobiology of Hearing Laboratory, Alberto Sols Institute of Biomedical Research CSIC-UAM, led by Prof. Isabel Varela-Nieto. The work, entitled "Evaluation of new therapies for the prevention of sensorineural hearing loss", is signed by researchers Silvia Murillo-Cuesta, Lourdes Rodríguez de la Rosa, Teresa Rivera, Fernando García-Alcántara, Lorena Sanz and Isabel Varela-Nieto. In addition, members of the Otorhinolaryngology Service of the Príncipe de Asturias University Hospital (Alcalá...
Isabel Varela-Nieto, has been elected to become a member of the Federation of European Biochemical Societies (FEBS)
Prof. Isabel Varela-Nieto, group leader of the Neurobiology of Hearing laboratory at the IIBm, has been elected to become a member of the Federation of European Biochemical Societies (FEBS), Science and Society Committee for the next three years (2017-2021). This prestigious society is a charitable organization that has supported research and education in molecular life sciences over the last fifty years.
The first edition of the Auditory Neuroscience Summer School took place 6-8 july in the UAM Department of Anatomy, and was attended by 21 students from 6 countries and 13 teachers, including international experts in preclinical trials and bioinformatics. This theoretical and practical course was organized by Prof. Carlos Avendaño (UAM), Prof. Isabel Varela-Nieto (CSIC), Silvia Murillo-Cuesta (CIBERER), Dr. Luis Lassaleta ("La Paz" University Hospital) and Dr. Esperanza Bas (Ear Institute, University of Miami), sponsored by the Marie Curie FP7-PEOPLE-TARGEAR network and with the support of CIBERER.
Isabel Varela-Nieto has been invited to serve on the International Committee of the Association for Research in Otolaryngology
Prof. Isabel Varela-Nieto, leader of the Neurobiology of hearing group, has been invited to serve on the International Committee of the Association for Research in Otolaryngology (ARO) for a three-year period. This prestigious association aims to encourage and promote research, both basic and clinical, in the broad field of Otolaryngology and related areas, especially in clinical genetics and diagnosis of mutations causing deafness.
Excmo. Sr. D. Sebastián Cerdán García-Esteller took office as academician of number of the Royal National Academy of Pharmacy on April 28th. His relatives, friends and colleagues attended at the Solemn Session where Excma. Sra. Dña. María Cascales Angosto , Academician of number of the RANF, replied him. Professor Sebastián Cerdán read the discourse entitled "The imaging time" in which he started analysing the role of the image in our society to focus afterwards in the biomedical imaging development along the last decades and in the contribution that has entailed to the medical advance and the study of the disease. Prof. Cerdán himself has notably contributed to the advance of preclinical imaging with the development of new Nuclear Magnetic Resonance (NMR) applications that allow studying, at structural,...
The Royal National Academy of Pharmacy awards IIBM scientists The Royal National Academy of Pharmacy has published the resolution of its 2015 Awards. Among the scientists receiving these awards several researchers of Instituto de Investigaciones Biomédicas Alberto Sols (IIBM) appear listed. Precisely, Virginia Pardo Marqués, Águeda González-Rodríguez y Ángela Martínez Valverde were the winners of the PREMIO DEL CONSEJO GENERAL DE COLEGIOS OFICIALES FARMACÉUTICOS for the work entitled "New therapeutic targets for the treatment od insulin resistance based on the interaction between hepatocytes and Kupffer cells", whereas María de los Angeles Pajares Tarancón was awarded the Accesit to the Premio de la Real Academia Nacional de Farmacia 2015 for the work entitled "The new levels of redox regulation of S-adenosylmethionine synthesis".
Pilar Santisteban has been elected President of the European Thyroid Association in the 15th International Thyroid Meeting (Orlando, Florida USA, October 2015)
Pilar Santisteban has been elected President of the European Thyroid Association in the 15th International Thyroid Meeting (Orlando, Florida USA, October 2015). The aims of this Association are to promote knowledge in the thyroid field (basic and clinical) and improve knowledge of the thyroid gland and its diseases. The Association was founded in 1965 and has met each year since then, with the exception of the years in which the International Thyroid Congress has been held. There are over 900 members. More details in www.eurothyroid.com